NewAmsterdam Pharma (NAMS) Competitors $24.19 -2.41 (-9.06%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$25.66 +1.47 (+6.08%) As of 09/12/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, and LEGNShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors Qiagen BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech NewAmsterdam Pharma (NASDAQ:NAMS) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Is NAMS or QGEN more profitable? Qiagen has a net margin of 18.30% compared to NewAmsterdam Pharma's net margin of -259.07%. Qiagen's return on equity of 14.77% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% Qiagen 18.30%14.77%8.87% Does the media prefer NAMS or QGEN? In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Qiagen. MarketBeat recorded 16 mentions for NewAmsterdam Pharma and 14 mentions for Qiagen. NewAmsterdam Pharma's average media sentiment score of 1.05 beat Qiagen's score of 1.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NAMS or QGEN? NewAmsterdam Pharma currently has a consensus target price of $41.55, indicating a potential upside of 71.75%. Qiagen has a consensus target price of $49.69, indicating a potential upside of 9.68%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Do institutionals & insiders have more ownership in NAMS or QGEN? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, NAMS or QGEN? Qiagen has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M59.80-$241.60M-$1.62-14.93Qiagen$2.04B4.94$83.59M$1.6926.80 Which has more volatility and risk, NAMS or QGEN? NewAmsterdam Pharma has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. SummaryNewAmsterdam Pharma and Qiagen tied by winning 8 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00B$2.59B$5.83B$10.13BDividend YieldN/A56.52%5.68%4.59%P/E Ratio-14.9323.8575.4125.98Price / Sales59.80537.41511.43293.19Price / CashN/A171.1637.5660.44Price / Book2.955.3712.156.29Net Income-$241.60M$32.95M$3.29B$271.07M7 Day Performance-10.41%1.28%0.74%3.87%1 Month Performance-3.89%5.61%5.00%5.49%1 Year Performance51.57%-1.67%62.55%25.86% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.3389 of 5 stars$24.19-9.1%$41.55+71.7%+51.6%$3.00B$45.56M-14.934News CoveragePositive NewsInsider TradeQGENQiagen4.4717 of 5 stars$46.53+0.9%$49.69+6.8%+0.5%$10.34B$1.98B27.495,765BBIOBridgeBio Pharma4.445 of 5 stars$51.76-1.5%$62.18+20.1%+95.6%$9.89B$221.90M-12.66400Analyst ForecastMRNAModerna4.4674 of 5 stars$24.09-1.6%$42.88+78.0%-65.6%$9.37B$3.24B-3.205,800News CoverageVRNAVerona Pharma PLC American Depositary Share2.3176 of 5 stars$105.91+0.0%$109.00+2.9%+257.4%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.6248 of 5 stars$18.38-0.4%$17.33-5.7%+28.0%$9.12B$4.44B21.379,000High Trading VolumeROIVRoivant Sciences3.144 of 5 stars$11.93-0.1%$16.38+37.3%+17.9%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions VolumeRVMDRevolution Medicines4.1921 of 5 stars$37.97-0.9%$69.92+84.2%+6.5%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.9832 of 5 stars$9.97+1.0%$10.30+3.3%+6.7%$6.85B$7.81B8.5223,822News CoverageRYTMRhythm Pharmaceuticals3.2551 of 5 stars$103.15-1.0%$101.57-1.5%+93.9%$6.85B$130.13M-34.27140Positive NewsLEGNLegend Biotech3.1903 of 5 stars$34.73+1.0%$74.22+113.7%-34.2%$6.41B$627.24M-39.472,609Positive News Related Companies and Tools Related Companies Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts